To obtain Papers by PMID numbers, use www.moremed.org
Your Search was translated by PubMed to (("covid-19"[MeSH Terms] OR "covid-19"[All Fields] OR "covid19"[All Fields]) OR ("COVID-19"[All Fields] OR "COVID-19"[MeSH Terms] OR "COVID-19 Vaccines"[All Fields] OR "COVID-19 Vaccines"[MeSH Terms] OR "COVID-19 serotherapy"[All Fields] OR "COVID-19 serotherapy"[Supplementary Concept] OR "COVID-19 Nucleic Acid Testing"[All Fields] OR "covid-19 nucleic acid testing"[MeSH Terms] OR "COVID-19 Serological Testing"[All Fields] OR "covid-19 serological testing"[MeSH Terms] OR "COVID-19 Testing"[All Fields] OR "covid-19 testing"[MeSH Terms] OR "SARS-CoV-2"[All Fields] OR "sars-cov-2"[MeSH Terms] OR "Severe Acute Respiratory Syndrome Coronavirus 2"[All Fields] OR "NCOV"[All Fields] OR "2019 NCOV"[All Fields] OR (("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields] OR "COV"[All Fields]) AND 2019/11/01[PDAT] : 3000/12/31[PDAT])) OR sars-cov2[All Fields] OR ("sars-cov-2"[MeSH Terms] OR "sars-cov-2"[All Fields] OR "sars cov 2"[All Fields]) OR ("sars-cov-2"[MeSH Terms] OR "sars-cov-2"[All Fields] OR "2019 ncov"[All Fields]) OR 2019ncov[All Fields]) AND (nsp10[All Fields] OR (non-structural[All Fields] AND ("proteins"[MeSH Terms] OR "proteins"[All Fields] OR "protein"[All Fields]) AND 10[All Fields]) OR nsp16[All Fields] OR (non-structural[All Fields] AND ("proteins"[MeSH Terms] OR "proteins"[All Fields] OR "protein"[All Fields]) AND 16[All Fields]) OR ("methyltransferases"[MeSH Terms] OR "methyltransferases"[All Fields] OR "methyltransferase"[All Fields]))

Shown are free items 1 to 150 of 247

Shown are unfree items 1 to 28 of 28

((covid19 OR covid-19 OR sars-cov2 OR sars-cov-2 OR 2019-ncov OR 2019ncov)) AND (nsp10 OR non-structural protein 10 OR nsp16 OR non-structural protein 16 OR methyltransferase))

NEXT PAGE

"number","email"
"1","pgrivas@uw.edu"
"2","janine.lamb@manchester.ac.uk"
"3","Joanna.Kowalska@fuw.edu.pl"
"4","ross.martin@gilead.com"
"5","nabavi208@gmail.com"
"6","agnes.marchio@pasteur.fr"
"7","helcio_santos@uvanet.br"
"8","lhgyx@hotmail.com"
"9","etdonas2@gmail.com"
"10","anita.krisko@med.uni-goettingen.de"
"11","tao-wang@zju.edu.cn"
"12","teresa.carlomagno@oci.uni-hannover.de"
"13","hengesbach@nmr.uni-frankfurt.de"
"14","banci@cerm.unifi.it"
"15","schlundt@bio.uni-frankfurt.de"
"16","shixinliu@rockefeller.edu"
"17","g.bowman@wustl.edu"
"18","giovanni.franzo@unipd.it"
"19","yan-gao13@mails.tsinghua.edu.cn"
"20","raozh@tsinghua.edu.cn"
"21","darst@rockefeller.edu"
"22","dev.Majumdar@med.uvm.edu"
"23","panjan@mail.sysu.edu.cn"
"24","weiy@niddk.nih.gov"
"25","wangjw28@163.com"
"26","diaohy@zju.edu.cn"
"27","dwchen@sicau.edu.cn"
"28","trana@ucsd.edu"
"29","hoxia@utmb.edu"
"30","rezwanuzzaman.laskar@gmail.com"
"31","nirajkumarjha2011@gmail.com"
"32","carmay@gate.sinica.edu.tw"
"33","efferth@uni-mainz.de"
"34","jerrine.cddd@sathyabama.ac.in"
"35","zlatka.plavec@helsinki.fi"
"36","anna.alisi@opbg.net"
"37","etienne.decroly@afmb.univ-mrs.fr"
"38","rujuta.rd@gmail.com"
"39","mail2tusharranjan@gmail.com"
"40","steven.lehrer@mssm.edu"
"41","steven.lehrer@mssm.edu"
"42","all@anticancer.com"
"43","tr@bt.iith.ac.in"
"44","mnizam@usm.my"
"45","gui_lingli@hotmail.com"
"46","bmzabdalla@gmail.com"
"47","deepak@rcb.res.in"
"48","mshamsi1@jmi.ac.in"
"49","dilekbalik@gmail.com"
"50","yongzhao168@gmail.com"
"51","jason.perry@gilead.com"
"52","stephane.richard@mcgill.ca"
"53","umeshchandrahalder@gmail.com"
"54","tpsaliu@futa.edu.ng"
"55","agmacabeo@ust.edu.ph"
"56","ariwajoye3@gmail.com"
"57","maria.lorenzo@ucv.ve"
"58","domenicobenvenuto95@gmail.com"
"59","anfuzimoto@fivebranches.edu"
"number","email"
"1","wxx6941@louisiana.edu"
"2","dimvl@aua.gr"
"3","oliver.muehlemann@dcb.unibe.ch"
"4","paul.olinares@rockefeller.edu"

PubNeph papers



Free papers



PMC8003899 1. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing.

3 Biotech 2021; 11 (4): 198

*33816047*
                       33816047

PMC8265718 2. The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors.

ACS Infect Dis 2021; 7 (8): 2214-2220

*34152728*
                       34152728

PMC8204913 3. Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate.

ACS Med Chem Lett 2021; 12 (7): 1102-1107

*34257831*
                       34257831

PMC8250829 4. Chemo-Enzymatic Modification of the 5' Cap Maintains Translation and Increases Immunogenic Properties of mRNA.

Angew Chem Int Ed Engl 2021; 60 (24): 13280-13286

*33751748*
                       33751748

PMC7972830 5. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Ann Oncol 2021; 32 (6): 787-800

*33746047*
                       33746047

PMC7509518 6. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis.

Ann Rheum Dis 2020; 79 (10): 1383-1386

*32444414*
                       32444414

PMC7607133 7. Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.

Ann Transl Med 2020; 8 (19): 1247

*33178779*
                       33178779

PMC8300634 8. Rhamnolipids Nano-Micelles as a Potential Hand Sanitizer.

Antibiotics (Basel) 2021; 10 (7):

*34206211*
                       34206211

PMC8300822 9. Strawberry and Ginger Silver Nanoparticles as Potential Inhibitors for SARS-CoV-2 Assisted by In Silico Modeling and Metabolic Profiling.

Antibiotics (Basel) 2021; 10 (7):

*34356745*
                       34356745

PMC8300629 10. Elucidation of Teicoplanin Interactions with Drug Targets Related to COVID-19.

Antibiotics (Basel) 2021; 10 (7):

*34356777*
                       34356777

PMC8299157 11. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.

Antiviral Res 2021; 193 (): 105142

*34303749*
                       34303749

PMC7862048 12. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.

Antiviral Res 2021; 188 (): 105033

*33549572*
                       33549572

PMC7261434 13. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?

Arch Med Res 2020; 51 (7): 733-735

*32536457*
                       32536457

PMC8273560 14. ddPCR increases detection of SARS-CoV-2 RNA in patients with low viral loads.

Arch Virol 2021; 166 (9): 2529-2540

*34251549*
                       34251549

PMC7751655 15. A multifactorial score including autophagy for prognosis and care of COVID-19 patients.

Autophagy 2020; 16 (12): 2276-2281

*33249989*
                       33249989

PMC7755319 16. Coronavirus interactions with the cellular autophagy machinery.

Autophagy 2020; 16 (12): 2131-2139

*32964796*
                       32964796

PMC8506486 17. Search for RNA aptamers against non-structural protein of SARS-CoV-2: Design using molecular dynamics approach.

Beni Suef Univ J Basic Appl Sci 2021; 10 (1): 64

*34660818*
                       34660818

PMC8257429 18. Peptide inhibitors against SARS-CoV-2 2'-O-methyltransferase involved in RNA capping: A computational approach.

Biochem Biophys Rep 2021; 27 (): 101069

*34250275*
                       34250275

PMC7750489 19. Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing.

Biochem Biophys Rep 2021; 25 (): 100847

*33364445*
                       33364445

PMC7547569 20. Identification of novel mutations in the methyltransferase complex (Nsp10-Nsp16) of SARS-CoV-2.

Biochem Biophys Rep 2020; 24 (): 100833

*33072893*
                       33072893

PMC7762712 21. In silico study of the potential interactions of 4'-acetamidechalcones with protein targets in SARS-CoV-2.

Biochem Biophys Res Commun 2021; 537 (): 71-77

*33387885*
                       33387885

PMC7144854 22. EZH2-mediated H3K27me3 inhibits ACE2 expression.

Biochem Biophys Res Commun 2020; 526 (4): 947-952

*32291076*
                       32291076

PMC8286817 23. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase.

Biochem J 2021; 478 (13): 2481-2497

*34198328*
                       34198328

PMC8286829 24. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.

Biochem J 2021; 478 (13): 2445-2464

*34198326*
                       34198326

PMC8286840 25. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease.

Biochem J 2021; 478 (13): 2517-2531

*34198325*
                       34198325

PMC8286823 26. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease.

Biochem J 2021; 478 (13): 2465-2479

*34198324*
                       34198324

PMC7078746 27. Processing of the SARS-CoV pp1a/ab nsp7-10 region.

Biochem J 2020; 477 (5): 1009-1019

*32083638*
                       32083638

PMC7200640 28. Expanding our understanding of the role polyprotein conformation plays in the coronavirus life cycle.

Biochem J 2020; 477 (8): 1479-1482

*32348474*
                       32348474

PMC7772802 29. Structure and Expression of Large (+)RNA Genomes of Viruses of Higher Eukaryotes.

Biochemistry (Mosc) 2021; 86 (3): 248-261

*33838627*
                       33838627

PMC8256665 30. In silico analysis of the aggregation propensity of the SARS-CoV-2 proteome: Insight into possible cellular pathologies.

Biochim Biophys Acta Proteins Proteom 2021; 1869 (10): 140693

*34237472*
                       34237472

PMC8221690 31. Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins.

Bioinform Biol Insights 2021; 15 (): 11779322211025876

*34220199*
                       34220199

PMC7671653 32. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection.

Biomed Pharmacother 2021; 133 (): 111035

*33254013*
                       33254013

PMC7568149 33. Phytochemicals from Selective Plants Have Promising Potential against SARS-CoV-2: Investigation and Corroboration through Molecular Docking, MD Simulations, and Quantum Computations.

Biomed Res Int 2020; 2020 (): 6237160

*33102585*
                       33102585

PMC7996116 34. (1)H, (13)C, and (15)N backbone chemical-shift assignments of SARS-CoV-2 non-structural protein 1 (leader protein).

Biomol NMR Assign 2021; 15 (2): 287-295

*33770349*
                       33770349

PMC7648550 35. (1)H, (13)C, and (15)N backbone chemical shift assignments of coronavirus-2 non-structural protein Nsp10.

Biomol NMR Assign 2021; 15 (1): 65-71

*33159807*
                       33159807

PMC7428200 36. (1)H, (13)C, and (15)N backbone chemical shift assignments of the apo and the ADP-ribose bound forms of the macrodomain of SARS-CoV-2 non-structural protein 3b.

Biomol NMR Assign 2020; 14 (2): 339-346

*32803496*
                       32803496

PMC7414254 37. (1)H, (13)C, and (15)N backbone chemical shift assignments of the nucleic acid-binding domain of SARS-CoV-2 non-structural protein 3e.

Biomol NMR Assign 2020; 14 (2): 329-333

*32770392*
                       32770392

PMC8003478 38. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).

Biomolecules 2021; 11 (3):

*33808721*
                       33808721

PMC8070809 39. Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10-nsp16 Complex of SARS-CoV-2.

Biomolecules 2021; 11 (4):

*33919870*
                       33919870

PMC7837305 40. Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase.

Biophys J 2021; 120 (6): 1020-1030

*33340543*
                       33340543

PMC8007187 41. SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential.

Biophys J 2021; 120 (14): 2880-2889

*33794150*
                       33794150

PMC7987004 42. A metal ion orients mRNA to ensure accurate 2'- O ribosyl methylation of the first nucleotide of the SARS-CoV-2 genome.

bioRxiv 2021; ():

*33758845*
                       33758845

PMC7899450 43. Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors.

bioRxiv 2021; ():

*33619486*
                       33619486

PMC8020977 44. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN.

bioRxiv 2021; ():

*33821277*
                       33821277

PMC7685324 45. Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.

bioRxiv 2020; ():

*33236014*
                       33236014

PMC7239068 46. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning.

bioRxiv 2020; ():

*32511333*
                       32511333

PMC7743098 47. SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential.

bioRxiv 2020; ():

*33330873*
                       33330873

PMC7263512 48. Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus.

bioRxiv 2020; ():

*32511383*
                       32511383

PMC7263505 49. The crystal structure of nsp10-nsp16 heterodimer from SARS-CoV-2 in complex with S-adenosylmethionine.

bioRxiv 2020; ():

*32511376*
                       32511376

PMC7857134 50. Genetic diversity and genomic epidemiology of SARS-CoV-2 in Morocco.

Biosaf Health 2021; 3 (2): 124-127

*33558859*
                       33558859

PMC8025453 51. Effect of genome composition and codon bias on infectious bronchitis virus evolution and adaptation to target tissues.

BMC Genomics 2021; 22 (1): 244

*33827429*
                       33827429

PMC7959154 52. Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines.

Braz J Med Biol Res 2021; 54 (5): e10725

*33729394*
                       33729394

PMC8063172 53. Identification of selected genes associated with the SARS-CoV-2: a therapeutic approach and disease severity.

Bull Natl Res Cent 2021; 45 (1): 79

*33907373*
                       33907373

PMC8142856 54. Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading.

Cell 2021; 184 (13): 3474-3485.e11

*34143953*
                       34143953

PMC7666536 55. Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis.

Cell 2021; 184 (1): 184-193.e10

*33232691*
                       33232691

PMC7386476 56. Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex.

Cell 2020; 182 (6): 1560-1573.e13

*32783916*
                       32783916

PMC7543886 57. SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses.

Cell 2020; 183 (5): 1325-1339.e21

*33080218*
                       33080218

PMC8295636 58. Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV-2 replication.

Cell Biosci 2021; 11 (1): 140

*34294141*
                       34294141

PMC8287290 59. SARS-CoV-2: from its discovery to genome structure, transcription, and replication.

Cell Biosci 2021; 11 (1): 136

*34281608*
                       34281608

PMC8527578 60. An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.

Cell Chem Biol 2021; ():

*34672954*
                       34672954

PMC8298984 61. RBM15-mediated N6-methyladenosine modification affects COVID-19 severity by regulating the expression of multitarget genes.

Cell Death Dis 2021; 12 (8): 732

*34301919*
                       34301919

PMC6971083 62. Transmissible gastroenteritis virus targets Paneth cells to inhibit the self-renewal and differentiation of Lgr5 intestinal stem cells via Notch signaling.

Cell Death Dis 2020; 11 (1): 40

*31959773*
                       31959773

PMC8090989 63. METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection.

Cell Rep 2021; 35 (6): 109091

*33961823*
                       33961823

PMC7501843 64. Evasion of Type I Interferon by SARS-CoV-2.

Cell Rep 2020; 33 (1): 108234

*32979938*
                       32979938

PMC8467010 65. Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets.

Cells 2021; 10 (9):

*34572076*
                       34572076

66. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.

Cells 2021; 10 (11):

*34831172*
                       34831172

PMC8067447 67. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.

Cells 2021; 10 (4):

*33917481*
                       33917481

PMC7291026 68. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.

Cells 2020; 9 (5):

*32443810*
                       32443810

PMC8299203 69. Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients.

Chem Biol Interact 2021; 347 (): 109598

*34303694*
                       34303694

PMC7505113 70. Deciphering the SSR incidences across viral members of Coronaviridae family.

Chem Biol Interact 2020; 331 (): 109226

*32971122*
                       32971122

PMC7936854 71. Biological perspective of thiazolide derivatives against Mpro and MTase of SARS-CoV-2: Molecular docking, DFT and MD simulation investigations.

Chem Phys Lett 2021; 771 (): 138463

*33716307*
                       33716307

PMC7835070 72. Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies.

Chem Phys Lett 2021; 767 (): 138379

*33518774*
                       33518774

PMC8032478 73. In silico investigation of potential small molecule inhibitors of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex.

Chem Phys Lett 2021; 774 (): 138618

*33850334*
                       33850334

PMC8162115 74. Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors.

Chem Sci 2020; 11 (36): 9904-9909

*34094251*
                       34094251

PMC8426721 75. Enzymatic Assays to Explore Viral mRNA Capping Machinery.

Chembiochem 2021; ():

*34291555*
                       34291555

PMC8133350 76. Computational Approaches to Discover Novel Natural Compounds for SARS-CoV-2 Therapeutics.

ChemistryOpen 2021; 10 (5): 593-599

*34010501*
                       34010501

PMC8434689 77. Anti-COVID-19 activity of some benzofused 1,2,3-triazolesulfonamide hybrids using in silico and in vitro analyses.

Chemometr Intell Lab Syst 2021; 217 (): 104421

*34538993*
                       34538993

PMC7668744 78. Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19.

ChemRxiv 2020; ():

*33200117*
                       33200117

PMC7668741 79. A Multi-Pronged Approach Targeting SARS-CoV-2 Proteins Using Ultra-Large Virtual Screening.

ChemRxiv 2020; ():

*33200116*
                       33200116

PMC8008812 80. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

Comput Biol Med 2021; 133 (): 104359

*33845270*
                       33845270

PMC8373586 81. Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery.

Comput Struct Biotechnol J 2021; 19 (): 4684-4701

*34426762*
                       34426762

PMC7527316 82. Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2'-O-Methyltransferase.

Comput Struct Biotechnol J 2020; 18 (): 2757-2765

*33020707*
                       33020707

PMC7456627 83. Warriors, Worriers, and COVID-19: An Exploratory Study of the Catechol O-Methyltransferase Val158Met Polymorphism Across Populations.

Cureus 2020; 12 (8): e10103

*32879833*
                       32879833

PMC8390070 84. Phytomolecules Repurposed as Covid-19 Inhibitors: Opportunity and Challenges.

Curr Microbiol 2021; 78 (10): 3620-3633

*34448061*
                       34448061

PMC8460353 85. Virus structure and structure-based antivirals.

Curr Opin Virol 2021; 51 (): 16-24

*34564030*
                       34564030

PMC7930934 86. Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic.

Diseases 2021; 9 (1):

*33535388*
                       33535388

PMC7246970 87. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.

Drugs 2020; 80 (10): 941-946

*32451923*
                       32451923

PMC8381960 88. Live attenuated coronavirus vaccines deficient in N7-Methyltransferase activity induce both humoral and cellular immune responses in mice.

Emerg Microbes Infect 2021; 10 (1): 1626-1637

*34365904*
                       34365904

PMC7832039 89. SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay.

Emerg Microbes Infect 2021; 10 (1): 51-65

*33306459*
                       33306459

PMC7473193 90. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists.

Emerg Microbes Infect 2020; 9 (1): 1418-1428

*32529952*
                       32529952

PMC7291971 91. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase.

Eur J Med Chem 2020; 201 (): 112557

*32563813*
                       32563813

PMC7398085 92. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.

Eur J Pharmacol 2020; 886 (): 173430

*32758569*
                       32758569

PMC8074651 93. Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.

Expert Opin Ther Pat 2021; 31 (4): 339-350

*33593200*
                       33593200

PMC7946385 94. Membrane remodeling by SARS-CoV-2 - double-enveloped viral replication.

Fac Rev 2021; 10 (): 17

*33718934*
                       33718934

PMC8573545 95. The histone methyltransferase Ezh2 restrains macrophage inflammatory responses.

FASEB J 2021; 35 (10): e21843

*34464475*
                       34464475

PMC8206714 96. Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development.

FASEB J 2021; 35 (5): e21573

*33913206*
                       33913206

PMC8237063 97. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2.

FEBS J 2021; 288 (17): 5130-5147

*33705595*
                       33705595

PMC7426555 98. COVID-19, cilia, and smell.

FEBS J 2020; 287 (17): 3672-3676

*32692465*
                       32692465

PMC8141588 99. Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics.

Front Chem 2021; 9 (): 636362

*34041221*
                       34041221

PMC7985531 100. Structural and Drug Screening Analysis of the Non-structural Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Virus Extracted From Indian Coronavirus Disease 2019 Patients.

Front Genet 2021; 12 (): 626642

*33767730*
                       33767730

PMC7933663 101. SARS-CoV-2 Infection-Induced Promoter Hypomethylation as an Epigenetic Modulator of Heat Shock Protein A1L (HSPA1L) Gene.

Front Genet 2021; 12 (): 622271

*33679887*
                       33679887

PMC8293103 102. ROS/RNS Balancing, Aerobic Fermentation Regulation and Cell Cycle Control - a Complex Early Trait ('CoV-MAC-TED') for Combating SARS-CoV-2-Induced Cell Reprogramming.

Front Immunol 2021; 12 (): 673692

*34305903*
                       34305903

PMC7350702 103. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.

Front Immunol 2020; 11 (): 1581

*32719684*
                       32719684

PMC8440879 104. Whole Genome Sequencing of SARS-CoV-2 Strains in COVID-19 Patients From Djibouti Shows Novel Mutations and Clades Replacing Over Time.

Front Med (Lausanne) 2021; 8 (): 737602

*34540874*
                       34540874

PMC7732651 105. Computational Investigation of Structural Dynamics of SARS-CoV-2 Methyltransferase-Stimulatory Factor Heterodimer nsp16/nsp10 Bound to the Cofactor SAM.

Front Mol Biosci 2020; 7 (): 590165

*33330626*
                       33330626

PMC7649796 106. Systematic Analysis of Coronavirus Disease 2019 (COVID-19) Receptor ACE2 in Malignant Tumors: Pan-Cancer Analysis.

Front Mol Biosci 2020; 7 (): 569414

*33195415*
                       33195415

PMC7365879 107. SARS-CoV-2 Molecular Network Structure.

Front Physiol 2020; 11 (): 870

*32754056*
                       32754056

PMC8044316 108. Bovine Coronavirus and the Associated Diseases.

Front Vet Sci 2021; 8 (): 643220

*33869323*
                       33869323

PMC7673215 109. Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.

Gene 2021; 768 (): 145313

*33220345*
                       33220345

PMC7452913 110. In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors.

Gene Rep 2020; 21 (): 100860

*32875166*
                       32875166

PMC8378035 111. Human Gene Sequences in SARS-CoV-2 and Other Viruses.

In Vivo 2020; 34 (3 Suppl): 1633-1636

*32503822*
                       32503822

PMC8378031 112. SARS-CoV-2 orf1b Gene Sequence in the NTNG1 Gene on Human Chromosome 1.

In Vivo 2020; 34 (3 Suppl): 1629-1632

*32503821*
                       32503821

PMC8378026 113. Oral Methioninase for Covid-19 Methionine-restriction Therapy.

In Vivo 2020; 34 (3 Suppl): 1593-1596

*32503816*
                       32503816

PMC7853258 114. Transcriptome & viral growth analysis of SARS-CoV-2-infected Vero CCL-81 cells.

Indian J Med Res 2020; 152 (1 & 2): 70-76

*32773420*
                       32773420

PMC8233849 115. Global variation in SARS-CoV-2 proteome and its implication in pre-lockdown emergence and dissemination of 5 dominant SARS-CoV-2 clades.

Infect Genet Evol 2021; 93 (): 104973

*34147651*
                       34147651

PMC8159710 116. Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.

Infect Genet Evol 2021; 93 (): 104944

*34052418*
                       34052418

PMC8010360 117. Molecular epidemiology analysis of early variants of SARS-CoV-2 reveals the potential impact of mutations P504L and Y541C (NSP13) in the clinical COVID-19 outcomes.

Infect Genet Evol 2021; 92 (): 104831

*33798758*
                       33798758

PMC7266387 118. Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms.

Inflamm Res 2020; 69 (8): 745-756

*32488318*
                       32488318

PMC7724963 119. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.

Int J Biol Macromol 2021; 168 (): 272-278

*33309661*
                       33309661

PMC7871800 120. Potential drug targets of SARS-CoV-2: From genomics to therapeutics.

Int J Biol Macromol 2021; 177 (): 1-9

*33577820*
                       33577820

PMC7513821 121. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).

Int J Biol Macromol 2020; 163 (): 1687-1696

*32980406*
                       32980406

PMC8495395 122. COVID-19 disease and malignant cancers: The impact for the furin gene expression in susceptibility to SARS-CoV-2.

Int J Biol Sci 2021; 17 (14): 3954-3967

*34671211*
                       34671211

PMC8297295 123. An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality.

Int J Environ Res Public Health 2021; 18 (13):

*34203568*
                       34203568

PMC8303145 124. COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases.

Int J Mol Sci 2021; 22 (14):

*34299101*
                       34299101

PMC8396565 125. SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites.

Int J Mol Sci 2021; 22 (16):

*34445741*
                       34445741

PMC7583907 126. Crystal Structure of Non-Structural Protein 10 from Severe Acute Respiratory Syndrome Coronavirus-2.

Int J Mol Sci 2020; 21 (19):

*33036230*
                       33036230

PMC7461590 127. New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.

Int J Mol Sci 2020; 21 (16):

*32824072*
                       32824072

PMC7966892 128. In-Silico Drug Designing of Spike Receptor with Its ACE2 Receptor and Nsp10/Nsp16 MTase Complex Against SARS-CoV-2.

Int J Pept Res Ther 2021; (): 1-8

*33746660*
                       33746660

PMC8310681 129. Target-Based In Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2.

Interdiscip Sci 2021; ():

*34308530*
                       34308530

PMC8494237 130. An atomistic model of the coronavirus replication-transcription complex as a hexamer assembled around nsp15.

J Biol Chem 2021; 297 (4): 101218

*34562452*
                       34562452

PMC8141346 131. Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication.

J Biol Chem 2021; 297 (1): 100821

*34029587*
                       34029587

PMC8331326 132. Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins.

J Biol Res (Thessalon) 2021; 28 (1): 18

*34344455*
                       34344455

PMC7443570 133. Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1).

J Biomol Struct Dyn 2021; 39 (15): 5657-5667

*32657643*
                       32657643

PMC7484570 134. In silico validation of coumarin derivatives as potential inhibitors against Main Protease, NSP10/NSP16-Methyltransferase, Phosphatase and Endoribonuclease of SARS CoV-2.

J Biomol Struct Dyn 2021; 39 (18): 7306-7321

*32835632*
                       32835632

PMC7189412 135. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.

J Biomol Struct Dyn 2021; 39 (8): 2679-2692

*32266873*
                       32266873

PMC7899166 136. Metabolomic profiling of three Araucaria species, and their possible potential role against COVID-19.

J Biomol Struct Dyn 2021; (): 1-13

*33596787*
                       33596787

PMC7885726 137. In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase.

J Biomol Struct Dyn 2021; (): 1-11

*33583328*
                       33583328

PMC7332864 138. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.

J Biomol Struct Dyn 2021; 39 (13): 4633-4646

*32573355*
                       32573355

PMC7332868 139. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.

J Biomol Struct Dyn 2021; 39 (13): 4582-4593

*32567979*
                       32567979

PMC7544923 140. Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus.

J Biomol Struct Dyn 2020; (): 1-16

*33016237*
                       33016237

PMC7784838 141. Design and in silico study of the novel coumarin derivatives against SARS-CoV-2 main enzymes.

J Biomol Struct Dyn 2020; (): 1-16

*33357038*
                       33357038

PMC7784784 142. Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation.

J Biomol Struct Dyn 2020; (): 1-11

*33317409*
                       33317409

PMC7946047 143. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.

J Enzyme Inhib Med Chem 2021; 36 (1): 727-736

*33685335*
                       33685335

PMC7656998 144. The potential antiviral effect of major royal jelly protein2 and its isoform X1 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Insight on their sialidase activity and molecular docking.

J Funct Foods 2020; 75 (): 104282

*33199981*
                       33199981

PMC8576800 145. Molecular docking and pharmacokinetic studies of phytocompounds from Nigerian Medicinal Plants as promising inhibitory agents against SARS-CoV-2 methyltransferase (nsp16).

J Genet Eng Biotechnol 2021; 19 (1): 172

*34751829*
                       34751829

PMC8284420 146. Anti-HIV reverse transcriptase plant polyphenolic natural products with in silico inhibitory properties on seven non-structural proteins vital in SARS-CoV-2 pathogenesis.

J Genet Eng Biotechnol 2021; 19 (1): 104

*34272647*
                       34272647

PMC7829640 147. Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus.

J Genet Eng Biotechnol 2021; 19 (1): 16

*33492492*
                       33492492

PMC8116314 148. Immunoinformatics and Pepscan strategies on the path of a peptide-based serological diagnosis of COVID19.

J Immunol Methods 2021; 495 (): 113071

*33991531*
                       33991531

PMC7195303 149. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy.

J Infect 2020; 81 (1): e24-e27

*32283146*
                       32283146

PMC8378675 150. An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.

J Integr Med 2021; 19 (5): 375-388

*34479848*
                       34479848

Beyond PubMed : called unfree



151. Literature review on virus and host response proteins in COVID-19: pathobiology, management, diagnosis and treatment.

Acta Virol 2021; 65 (1): 10-26

*33112638*
                       33112638

152. A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2.

Comb Chem High Throughput Screen 2021; 24 (9): 1482-1491

*33155887*
                       33155887

153. Exploring the effectiveness of the TSR-based protein 3-D structural comparison method for protein clustering, and structural motif identification and discovery of protein kinases, hydrolases, and SARS-CoV-2's protein via the application of amino acid grouping.

Comput Biol Chem 2021; 92 (): 107479

*33951604*
                       33951604

154. Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed.

Curr Med Chem 2021; 28 (12): 2392-2408

*32881656*
                       32881656

155. SARS-CoV-2 proteins: Are they useful as targets for COVID-19 drugs and vaccines?

Curr Mol Med 2021; ():

*33622224*
                       33622224

156. Silybin B and Cianidanol Inhibit M(pro) and Spike Protein of SARS-CoV-2: Evidence from in silico Molecular Docking Studies.

Curr Pharm Des 2021; 27 (32): 3476-3489

*33302853*
                       33302853

157. Epigenetic modifications of RNA and their implications in antiviral immunity.

Epigenomics 2020; 12 (19): 1673-1675

*33078621*
                       33078621

PMC8581826 158. Structural analysis of SARS-Cov-2 nonstructural protein 1 polymorphisms found in the Brazilian Amazon.

Exp Biol Med (Maywood) 2021; 246 (21): 2332-2337

*34749522*
                       34749522

PMC8247602 159. Targeting the m(6)A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication.

Genes Dev 2021; 35 (13-14): 1005-1019

*34168039*
                       34168039

160. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.

J Biomol Struct Dyn 2021; 39 (17): 6713-6727

*32741322*
                       32741322

161. Network analysis, sequence and structure dynamics of key proteins of coronavirus and human host, and molecular docking of selected phytochemicals of nine medicinal plants.

J Biomol Struct Dyn 2021; 39 (16): 6195-6217

*32686993*
                       32686993

162. Identification and structural studies of natural inhibitors against SARS-CoV-2 viral RNA methyltransferase (NSP16).

J Biomol Struct Dyn 2021; (): 1-11

*34766876*
                       34766876

163. Structural screening into the recognition of a potent inhibitor against non-structural protein 16: a molecular simulation to inhibit SARS-CoV-2 infection.

J Biomol Struct Dyn 2021; (): 1-16

*34762019*
                       34762019

164. Emetine, a potent alkaloid for the treatment of SARS-CoV-2 targeting papain-like protease and non-structural proteins: pharmacokinetics, molecular docking and dynamic studies.

J Biomol Struct Dyn 2021; (): 1-14

*34254564*
                       34254564

165. Identification of naphthyridine and quinoline derivatives as potential Nsp16-Nsp10 inhibitors: a pharmacoinformatics study.

J Biomol Struct Dyn 2020; (): 1-8

*33252031*
                       33252031

166. Finding Druggable Sites in Proteins Using TACTICS.

J Chem Inf Model 2021; 61 (6): 2897-2910

*34096704*
                       34096704

167. Possible Potential Outcomes from COVID-19 Complications on Testes: Lesson from SARS Infection.

J Coll Physicians Surg Pak 2020; 30 (10): 118-120

*33115584*
                       33115584

168. In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans.

J Med Virol 2021; 93 (4): 2476-2486

*33404091*
                       33404091

PMC8274614 169. Structural Analysis of the OC43 Coronavirus 2'-O-RNA Methyltransferase.

J Virol 2021; 95 (15): e0046321

*34011548*
                       34011548

170. The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.

JAMA Oncol 2021; 7 (5): 675-676

*33475680*
                       33475680

171. Genetic and structural analyses of ssRNA viruses pave the way for the discovery of novel antiviral pharmacological targets.

Mol Omics 2021; 17 (3): 357-364

*33725065*
                       33725065

172. Generation and Characterization of Monoclonal Antibody Against Porcine Epidemic Diarrhea Virus Nonstructural Protein 13.

Monoclon Antib Immunodiagn Immunother 2020; 39 (6): 222-227

*33351712*
                       33351712

173. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation.

Nat Struct Mol Biol 2020; 27 (10): 959-966

*32908316*
                       32908316

174. Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition.

Phytother Res 2021; 35 (2): 908-919

*32964551*
                       32964551

175. Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme.

Science 2021; 373 (6559): 1142-1146

*34315827*
                       34315827

PMC7867593 176. Native Mass Spectrometry-Based Screening for Optimal Sample Preparation in Single-Particle Cryo-EM.

Structure 2021; 29 (2): 186-195.e6

*33217329*
                       33217329

177. L'epigenetique, une nouvelle cible therapeutique lors des infections virales.

Virologie (Montrouge) 2021; 25 (2): 63-92

*33973852*
                       33973852

178. Porcine deltacoronavirus nsp10 antagonizes interferon-beta production independently of its zinc finger domains.

Virology 2021; 559 (): 46-56

*33813212*
                       33813212


The checkboxes will funnel the pmids of the checked items to a new window of multiple emerging functions. Do not check more than 100 records at one time. Press green button to proceed.
NEXT PAGE
MB